For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study for Patients with Newly Diagnosed B-Lymphoblastic Leukemia or B-Lineage Lymphoblastic Lymphoma

Clinical Trial Title: 
Treatment of patients with newly diagnosed standard risk B-lymphoblastic leukemia (B-ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy).
Clinical Trial Protocol ID: 
10080902-IRB01-AM09
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

To determine if a maintenance regimen containing weekly oral methotrexate at 40mg/m2/week will result in an improved disease free survival (DFS) compared to that containing weekly oral methotrexate at 20mg/m2/week in the average risk subset of patients with standard risk B-ALL.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have newly diagnosed NCI standard risk B-ALL or B-LLy Murphy Stages I or II.
  • Have an initial white blood cell count < 50,000/uL.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane